Studies showed that genetic variants in SELENOP were associated with the risk of breast cancer, prostate cancer, advanced colorectal adenoma and colorectal cancer as well as first phase insulin response and the occurrence of abdominal aortic aneurysm [19–24]. The gene discussed is INS; the disease is prostate cancer.